With approval from Health Canada, Taysha Gene Therapies will begin a Phase 1/2 clinical trial testing TSHA-118, its investigational gene therapy for CLN1 disease, also known as infantile Batten disease. This first trial will launch at Queen’s University, in Ontario, under the coordination of Jagdeep Walia, MD, with initial data expected by June, the company said in a press release. Taysha also has an open investigational new drug (IND) application in the U.S. for TSHA-118. “We believe…

You must be logged in to read/download the full post.